MARAVIROC Drug Patent Profile
✉ Email this page to a colleague
When do Maraviroc patents expire, and when can generic versions of Maraviroc launch?
Maraviroc is a drug marketed by Hetero Labs Ltd Iii and I 3 Pharms and is included in two NDAs.
The generic ingredient in MARAVIROC is maraviroc. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the maraviroc profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Maraviroc
A generic version of MARAVIROC was approved as maraviroc by HETERO LABS LTD III on February 7th, 2022.
Summary for MARAVIROC
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 91 |
Clinical Trials: | 140 |
Patent Applications: | 5,576 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for MARAVIROC |
DailyMed Link: | MARAVIROC at DailyMed |
Recent Clinical Trials for MARAVIROC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 1/Phase 2 |
Orlando Immunology Center | Phase 4 |
CCINSHAE. Secretaría de Salud. México | Phase 2 |
Pharmacology for MARAVIROC
Drug Class | CCR5 Co-receptor Antagonist |
Mechanism of Action | Chemokine Co-receptor 5 Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for MARAVIROC
US Patents and Regulatory Information for MARAVIROC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hetero Labs Ltd Iii | MARAVIROC | maraviroc | TABLET;ORAL | 203347-001 | Feb 7, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
I 3 Pharms | MARAVIROC | maraviroc | TABLET;ORAL | 217114-002 | Aug 17, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hetero Labs Ltd Iii | MARAVIROC | maraviroc | TABLET;ORAL | 203347-002 | Feb 7, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MARAVIROC
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
ViiV Healthcare B.V. | Celsentri | maraviroc | EMEA/H/C/000811 Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable, |
Authorised | no | no | no | 2007-09-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |